Tricida, a late-stage biotech developing therapies for conditions associated with CKD, filed on Monday with the SEC to raise up to $150 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol TCDA. Tricida filed confidentially on March 1, 2018. Goldman Sachs, J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
